ATTR amyloidosis is a rare condition that can affect several organs and tissues within the body through the accumulation of misfolded transthyretin protein deposits. NTLA-2001 is the first CRISPR therapy to be administered systemically to edit a disease-causing gene inside the human body, Intellia said.

In June 2021, Intellia and its collaborator Regeneron released positive interim clinical results from the first two cohorts of a phase I study of MTLA-2001 in adults with hereditary ATTR amyloidosis with polyneuropathy. The results were the first from a clinical trial evaluating the safety and efficacy of CRISPR genome editing in humans, the company said.

Next-generation gene therapy points to base editing
Base editing has emerged as a new player in the gene therapy arena, with rapid advances in technology and evidence of proof of concept in rare genetic...

Intellia reports net loss in Q2
Intellia Therapeutics reported a net loss for the second quarter of 2021, which ended June 30.

Intellia, Regeneron highlight clinical results for CRISPR-Cas9 gene therapy
Intellia Therapeutics and Regeneron Pharmaceuticals have announced positive interim data from an ongoing phase I study of their in vivo candidate, NTLA-2001,...

Blackstone, Intellia, Cellex to launch company addressing limitations of cell therapies
Blackstone Life Sciences has committed $250 million toward the launch of a new autologous and allogeneic universal chimeric antigen receptor T-cell...

Potential of gene editing for clinical use highlighted at ASGCT 2021
From base editing to in vivo CRISPR therapeutics and CRISPR-modified bacteriophages, scientists discussed innovations in preclinical research that have...